These therapies harness Cas13′s ability to selectively degrade pathogenic RNAs—MECP2 mRNA in MDS and VEGFA mRNA in nAMD—offering a programmable, transcript-specific approach for treating these diseases [274,275]. Here, MECP2 is linked to myelodysplastic syndrome.